Literature DB >> 17314346

Synergistic copathogens--HIV-1 and HSV-2.

Lawrence Corey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17314346     DOI： 10.1056/NEJMe068302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  57 in total

1.  Genital herpes simplex virus type 2 infection in humanized HIV-transgenic mice triggers HIV shedding and is associated with greater neurological disease.

Authors:  Briana Nixon; Esra Fakioglu; Martha Stefanidou; Yanhua Wang; Monica Dutta; Harris Goldstein; Betsy C Herold
Journal:  J Infect Dis       Date:  2013-08-29       Impact factor: 5.226

2.  Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication.

Authors:  Graciela Andrei; Andrea Lisco; Christophe Vanpouille; Andrea Introini; Emanuela Balestra; Joost van den Oord; Tomas Cihlar; Carlo-Federico Perno; Robert Snoeck; Leonid Margolis; Jan Balzarini
Journal:  Cell Host Microbe       Date:  2011-10-20       Impact factor: 21.023

3.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

Authors:  Glenda E Gray; Mary Allen; Zoe Moodie; Gavin Churchyard; Linda-Gail Bekker; Maphoshane Nchabeleng; Koleka Mlisana; Barbara Metch; Guy de Bruyn; Mary H Latka; Surita Roux; Matsontso Mathebula; Nivashnee Naicker; Constance Ducar; Donald K Carter; Adrien Puren; Niles Eaton; M Julie McElrath; Michael Robertson; Lawrence Corey; James G Kublin
Journal:  Lancet Infect Dis       Date:  2011-05-11       Impact factor: 25.071

4.  A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.

Authors:  Christophe Vanpouille; Andrea Lisco; Marco Derudas; Elisa Saba; Jean-Charles Grivel; Beda Brichacek; Francesca Scrimieri; Raymond Schinazi; Dominique Schols; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

5.  Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease.

Authors:  David M Naeger; Jeffrey N Martin; Elizabeth Sinclair; Peter W Hunt; David R Bangsberg; Frederick Hecht; Priscilla Hsue; Joseph M McCune; Steven G Deeks
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

6.  Previous reproductive history and post-natal family planning among HIV-infected women in Ukraine.

Authors:  J Saxton; R Malyuta; I Semenenko; T Pilipenko; R Tereshenko; E Kulakovskaya; I Adejnova; L Kvasha; C Thorne
Journal:  Hum Reprod       Date:  2010-07-19       Impact factor: 6.918

7.  Herpes simplex virus 2 (HSV-2) prevents dendritic cell maturation, induces apoptosis, and triggers release of proinflammatory cytokines: potential links to HSV-HIV synergy.

Authors:  Martha Stefanidou; Irene Ramos; Veronica Mas Casullo; Janie B Trépanier; Sara Rosenbaum; Ana Fernandez-Sesma; Betsy C Herold
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 8.  Research gaps in defining the biological link between HIV risk and hormonal contraception.

Authors:  Kerry Murphy; Susan C Irvin; Betsy C Herold
Journal:  Am J Reprod Immunol       Date:  2014-02-19       Impact factor: 3.886

9.  Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.

Authors:  Ashok Cattamanchi; Christine M Posavad; Anna Wald; Yaela Baine; Jennifer Moses; Terry J Higgins; Richard Ginsberg; Richard Ciccarelli; Lawrence Corey; David M Koelle
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

10.  Effects of genital ulcer disease and herpes simplex virus type 2 on the efficacy of male circumcision for HIV prevention: Analyses from the Rakai trials.

Authors:  Ronald H Gray; David Serwadda; Aaron A R Tobian; Michael Z Chen; Frederick Makumbi; Tara Suntoke; Godfrey Kigozi; Fred Nalugoda; Boaz Iga; Thomas C Quinn; Lawrence H Moulton; Oliver Laeyendecker; Steven J Reynolds; Xiangrong Kong; Maria J Wawer
Journal:  PLoS Med       Date:  2009-11-24       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.